Key Highlights

  • Boston Scientific (NYSE:BSX) fell 5.8% to 6.3% on October 28, 2026, after its fourth-quarter outlook, according to the company release and published market data, a drop of about 6%.
  • The shares fell as much as 11% early in the session before recovering part of the loss, so intraday selling was nearly twice the size of the closing decline.
  • One recap says fourth-quarter sales will be 1% to 3% below a year earlier, but that wording looks odd for a growth company and must be confirmed against the release.
  • Stryker (NYSE:SYK) reports after the close on October 29, 2026, with consensus earnings per share of USD 3.56, offering a read on whether medical device demand is softening more widely.

The Outlook and the Move

Boston Scientific (NYSE:BSX) shares fell 5.8% to 6.3% on October 28, 2026, after the company's fourth-quarter outlook, with an early low of 11% down, according to published market data. The direction of the guide is verified as weaker than hoped. One recap says fourth-quarter sales will be 1% to 3% below a year earlier, but that wording is unusual for a company that has generally grown sales, and the file reviewed advises confirming it. It may be a mangled growth rate or a comparison to a prior forecast, so readers should treat the 1% to 3% figure as unconfirmed pending the company release. Because the reviewed material did not include the third-quarter results themselves, this article cannot say whether the quarter beat estimates.

Why Guidance Moves Medtech

Medical device companies are valued on steady procedure growth, so a fourth-quarter outlook that disappoints can reset expectations for the next year. For Boston Scientific (NYSE:BSX), a maker of devices used in cardiology and other procedures, guidance matters because analysts build models from quarterly targets and annual ranges. If management trims the near-term path, the market may cut its estimate of the full-year result and apply a lower multiple. The early drop of 11% followed by a smaller close suggests buyers stepped in after the first reaction, a pattern that can occur when an initial headline reading proves harsher than the detail. Investors also watch how a decline compares with peers, since a company-specific cut is treated differently from an industry slowdown.

Risks and What to Watch

The main uncertainty is the exact guidance wording. Readers should check the release for the sales range, earnings per share outlook and any commentary on procedure volumes or pricing. Other healthcare names report soon: Gilead, Stryker (NYSE:SYK) and Illumina all report after the close on October 29, 2026, according to company calendars, which may show whether pressure is company specific or sector wide. Boston Scientific (NYSE:BSX) also faces broader market risk, since Nasdaq-100 futures were down about 1.2% at 4:09 a.m. ET on October 29. This outlook may be revised in future updates. Investors should avoid assuming the early low marks a floor, as intraday extremes often reverse.

Where Things Stand

Boston Scientific (NYSE:BSX) slid about 6% because its fourth-quarter outlook disappointed, though the exact wording, reported as sales 1% to 3% below a year earlier, looks odd and needs confirmation. The early loss reached 11% before easing. The next catalysts are Stryker (NYSE:SYK) results on October 29, 2026 and the company's own guidance detail. The wording issue is the key open fact. Readers should confirm the guide directly in the release. This is not investment advice.